Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
November 17 2020 - 8:00AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced the appointment of Nicole S. White,
PhD, as Senior Vice President of Pharmaceutical Development and
Manufacturing. Dr. White brings over 20 years of experience
overseeing the complexities of the chemistry manufacturing and
controls process.
“Nicole will be a tremendous asset to Assembly Bio as we
continue to progress our clinical development efforts, and we are
thrilled to welcome her to the company,” said John McHutchison, AO,
MD, Chief Executive Officer and President. “She is an established
leader with proven success guiding programs throughout the entirety
of the clinical lifecycle and ultimately to production of the
commercial supply. Nicole will play a key strategic role in the
advancement of our pipeline of core inhibitors, including
vebicorvir, which we are preparing for Phase 3 studies next
year.”
"I am excited to join the leadership team at Assembly Bio and to
work alongside this group of world-class experts in virology,” said
Dr. White. “The potential for core inhibitors to improve outcomes
for people with HBV is something that I have followed with great
interest, and I am eager to apply my experience and strong
technical background to support the company’s commitment to bring
new and long overdue treatment options to patients with chronic
HBV.”
Prior to joining Assembly Bio, Dr. White headed Process
Chemistry at Gossamer Bio and led chemistry, manufacturing and
controls (CMC) for multiple early- and late-stage programs in
development. Prior to that she held progressive leadership roles at
Gilead Sciences to advance multiple programs from Phase 1 through
commercial launch and helped guide the drug substance manufacturing
and global outsourcing strategy. While at Gilead, Dr. White
contributed to the development and commercial launch of multiple
antiviral programs including Harvoni®, Vemlidy® and Vosevi®. She
obtained a PhD in Organic Chemistry from the University of
California, Irvine and a BS in Chemistry from the University of
California, San Diego.
About Assembly BiosciencesAssembly Biosciences,
Inc. is a clinical-stage biotechnology company developing
innovative therapeutics targeting hepatitis B virus (HBV) and
diseases associated with the microbiome. The HBV program is focused
on advancing a new class of potent, oral core inhibitors that have
the potential to increase cure rates for chronically infected
patients. The microbiome program is developing novel oral live
microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP manufacturing expertise and
targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information, visit
assemblybio.com.
Forward-Looking Statements The information in
this press release contains forward-looking statements regarding
future events, including statements about the therapeutic potential
of our HBV product candidates. Certain forward-looking statements
may be identified by reference to a future period or by use of
forward-looking terminology such as “will,” “advance,” and
“progress.” Assembly Bio intends such forward-looking statements to
be covered by the safe harbor provisions contained in Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. More information about
Assembly Bio’s risks and uncertainties are more fully detailed
under the heading “Risk Factors” in Assembly Bio's filings with the
SEC, including its most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Except as required by law, Assembly Bio assumes no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Investor ContactAssembly
Biosciences, Inc.Lauren GlaserSenior Vice President, Investor
Relations and Corporate Affairs(415)
521-3828lglaser@assemblybio.com
Media ContactSam Brown Inc.Audra Friis(917)
519-9577ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024